Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs

Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.

Eye Close
Roche updated investors on its ophthalmology pipeline • Source: Shutterstock

With Roche Holding AG's new wet age-related macular degeneration (AMD) and diabetic eye disease drug Vabysmo (faricimab) off to an impressive early commercial launch, the company showcased the eye drugs it hopes will follow Vabysmo to market during a virtual investor event on 13 February connected to the Angiogenesis, Exudation and Degeneration 2023 Virtual Congress.

The broad clinical stage pipeline is part of a substantial commitment to the ophthalmology therapeutic area. Roche is testing nine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Sensory

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

More from Therapy Areas

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.